Sign in
Not yet taking people in South KoreaNo phase

Cuffless wearable versus office blood pressure readings to guide hypertension care

Compares two ways of guiding blood pressure treatment in adults with hypertension.

Key facts

Who runs it
Seoul National University Hospital
Where
Daegu, Seongnam-si, Seoul, and Uijeongbu-si, South KoreaSee the 9 sites
Trial code
Registry title
Comparison of Office and Cuffless Ambulatory Blood Pressure-Guided Management in Patients With Hypertension
Status
Not yet recruiting
People taking part
3,000 people, planned
Started
24 Aug 2026
Expected to end
31 Dec 2036
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Cuffless ambulatory blood pressure-guided management
  • Office blood pressure-guided management
Record updated
18 August 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults aged 30 to 79 with high blood pressure, shown by a wearable cuffless 24-hour blood pressure monitor. It compares two ways of guiding treatment.

Age
30 years up to under 80 years
Sex
All sexes can join.
Disease stage
High blood pressure: average systolic (top number) pressure over 24 hours of 130 mmHg or more on a cuffless ambulatory monitor.
Earlier treatment
The trial cannot take people with a recent stroke, heart attack or unstable angina hospital stay (within 6 months), or recent heart artery procedures (within 12 months).
Biomarker or test result
24 hour mean SBP ≥ 130 mmHg by cuffless ambulatory BP monitor.

Main reasons for not taking part

  • Office SBP ≥ 190 mmHg, or diastolic BP (DBP) < 60 mmHg
  • Secondary hypertension diagnosed
  • Sustained atrial fibrillation or ventricular arrhythmias that affect the ring-type cuffless device
  • Severe kidney problems, including dialysis, eGFR <30 ml/min/1.73m², or serum creatinine >2.5 mg/dL (221 µmol/L)
  • Cancer within the last 5 years

The registry criteria, word for word

Show all 19 criteriaShow less

Who can take part

  • 24 hour mean SBP ≥ 130 mmHg by cuffless ambulatory BP monitor
  • aged ≥30 and <80 years
  • voluntarily decide to participate in this clinical trial and provide written informed consent after being adequately informed
  • willing and able to comply with the requirements of the study protocol

Who cannot take part

  • Diagnosed secondary hypertension
  • Hospitalization for stroke, myocardial infarction (MI) or unstable angina within the last 6 months
  • History of sustained atrial fibrillation (AF) or ventricular arrhythmias at entry influencing the BP measurement of ring-type cuffless BP monitoring device
  • Severe valvular disease or valvular disease likely to require surgery or percutaneous valve replacement during the trial
  • Underlying heart disease: Hypertrophic cardiomyopathy (HCM), dilated cardiomyopathy (DCM), rheumatic heart disease or congenital heart disease
  • Malignancy history within 5 years
  • Severe cognitive impairment or mental disorders
  • Uncontrolled diabetes mellitus (serum fasting glucose > 200 mg/dL or glycated hemoglobin [HbA1c] >8%)
  • Severe liver dysfunction (alanine aminotransferase [ALT] > 3 times the upper limit of normal (ULN) value)
  • Severe renal dysfunction (end stage renal disease [ESRD] on dialysis or estimated glomerular filtration rate [eGFR] <30 ml/min/1.73m², or serum creatinine >2.5 mg/dL
  • Did not agree with this clinical trial and did not provide informed consent
  • Office SBP ≥ 190 mmHg, or diastolic BP (DBP) < 60 mmHg
  • Coronary revascularization (percutaneous coronary intervention [PCI] or coronary artery bypass grafting [CABG]) within the last 12 months
  • Planned to perform coronary revascularization (PCI or CABG) in the next 12 months
  • Participating in other clinical trials other than observation registry

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 30 and 79 years old?

Where in South Korea

  • Kyungpook National University HospitalDaegu, South KoreaContact: Jang Hoon Lee, MD, PhDNot yet recruiting
  • Seoul National University Bundang HospitalSeongnam-si, South KoreaContact: Kwang-Il Kim, MD, PhDNot yet recruiting
  • Korea University Anam HospitalSeoul, South KoreaContact: Hyung Joon Joo, MD, PhDNot yet recruiting
  • Korea University Guro HospitalSeoul, South KoreaContact: Ji Young YoonNot yet recruiting
  • Kyung Hee University Hospital at GangdongSeoul, South KoreaContact: Il-Suk Sohn, MD, PhDNot yet recruiting
  • Seoul National University Boramae Medical CenterSeoul, South KoreaContact: Hack-Lyoung Kim, MD, PhDNot yet recruiting
  • Seoul National University HospitalSeoul, South KoreaContact: Hae-Young Lee, MD, PhDNot yet recruiting
  • The Catholic University of Korea, Seoul ST. Mary's HospitalSeoul, South KoreaContact: Woo-Baek Chung, MD, PhDNot yet recruiting
  • The Catholic University of Korea Uijeongbu St. Mary's HospitalUijeongbu-si, South KoreaContact: Hyo-Suk Ahn, MD, PhDNot yet recruiting

About the trial

What the trial wants to find out

Hypertension is a major risk factor for cardiovascular and cerebrovascular diseases, including stroke and myocardial infarction. Blood pressure (BP) fluctuates throughout the day in response to physical activity, emotional states, and sleep. However, hypertension diagnosis and management are commonly based on BP measurements obtained in the clinic or at home, which may not fully reflect these variations. This can contribute to discrepancies between office and out-of-office BP, including white-coat and masked hypertension.

Read full original descriptionShow less

Ambulatory blood pressure monitoring (ABPM) provides information on BP throughout daily activities and sleep, but conventional cuff-based ABPM may be limited by discomfort, accessibility, and logistical challenges. Recently, cuffless wearable devices have enabled repeated BP monitoring without the use of a conventional inflatable cuff.

The CUFFLESS study is a multicenter, prospective, randomized controlled trial comparing two strategies for the management of hypertension: cuffless ambulatory BP-guided management and conventional office BP-guided management. Participants will be randomly assigned to either management strategy and followed for clinical outcomes. The primary objective is to determine whether hypertension management guided by cuffless ambulatory BP monitoring reduces the occurrence of cardiovascular events compared with management guided by conventional office BP measurements.

The 2 groups in the trial

  • Cuffless ambulatory blood pressure-guided management groupTreatment being tested

    Participants assigned to this group will receive hypertension management guided by both office blood pressure and 24-hour ambulatory blood pressure measured using a cuffless BP monitoring device.

    Treatment: Cuffless ambulatory blood pressure-guided management

  • Office blood pressure-guided management groupExisting treatment, for comparison

    Participants assigned to this group will receive conventional hypertension management guided by office blood pressure measurements.

    Treatment: Office blood pressure-guided management

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Comparison of Clinical Outcomes Between Office and Cuffless Ambulatory Blood Pressure-guided Management in Patients With Hypertension
Plain-language title
Cuffless wearable versus office blood pressure readings to guide hypertension careGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Fit questions
Built from NCT07770477, who can take part
Record updated
18 August 2026